<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03460405</url>
  </required_header>
  <id_info>
    <org_study_id>Typhoid 0218</org_study_id>
    <nct_id>NCT03460405</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants</brief_title>
  <official_title>Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Indonesian Adults, Adolescents, Children and Infants (Phase II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety and immunogenicity of Vi-DT vaccine in adults, adolescent,
      children and infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To describe the safety of this vaccine following one dose immunization in adults, adolescent,
      children and infants.

      To assess immunogenicity following one dose of Vi-DT vaccine immunization. To compare the
      safety and immunogenicity of Vi-DT to Vi polysaccharide vaccine in adults, adolescents, and
      children groups.

      To compare the safety and immunogenicity of Vi-DT to IPV vaccine in infants groups.

      Kinetics of Vi-specific IgG antibodies up to 6 months and 1 year after administration of 1
      dose of vaccine.

      To evaluate the safety and immunogenicity of Vi-DT co-administered with MR vaccine in infants
      (≥ 9months -23 months old).

      To evaluate the safety and immunogenicity of MR vaccine co-administered with Vi-DT vaccine in
      infants (≥ 9months -23 months old).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 19, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subject aged 2 - 40 years old:
Randomized, observer-blind, superiority design compared to Vi polysaccharide vaccine.
Subject aged 6-23 months old:
Randomized, observer-blind, superiority design compared to Inactivated Poliomyelitis Vaccine (IPV).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Subject aged 2 - 40 years old:
Randomized, observer-blind, superiority design compared to Vi polysaccharide vaccine.
Subject 6-23 months old:
Randomized, observer-blind, superiority design compared to Inactivated Poliomyelitis Vaccine (IPV).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Local reaction and systemic event after vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects with at least one immediate reaction (local reaction or systemic event) after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events after vaccination</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Percentage of subjects with at least one of these adverse events, solicited or not, within 24 h, 48h, 72h and 28 days after 1 dose vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events after vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>Number and percentage of subjects with serious adverse event from inclusion until 28 day after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT)</measure>
    <time_frame>28 days</time_frame>
    <description>Geometric Mean Titers (GMT) 28 days following immunization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with increasing antibody titer &gt;= 4 times</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects with increasing antibody titer &gt;= 4 times in all subjects</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Safety Issues</condition>
  <condition>Immunogenicity</condition>
  <arm_group>
    <arm_group_label>VI-DT vaccine (adults,adolescent)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml Vi-DT vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi polysaccharide (adults,adolescent)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 0.5 ml Vi polysaccharide vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-DT vaccine (children)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml Vi-DT vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi polysaccharide vaccine (children)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 0.5 ml Vi polysaccharide vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-DT vaccine (infants)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 0.5 ml Vi-DT vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPV Vaccine (infants)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 0.5 ml IPV vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi-DT Vaccine</intervention_name>
    <description>1 dose of Vi-DT Vaccine</description>
    <arm_group_label>VI-DT vaccine (adults,adolescent)</arm_group_label>
    <arm_group_label>VI-DT vaccine (children)</arm_group_label>
    <arm_group_label>VI-DT vaccine (infants)</arm_group_label>
    <other_name>Typhoid Conjugate Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi Polysaccharide Vaccine</intervention_name>
    <description>1 dose of Vi Polysaccharide Vaccine</description>
    <arm_group_label>Vi polysaccharide (adults,adolescent)</arm_group_label>
    <arm_group_label>Vi polysaccharide vaccine (children)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IPV Vaccine</intervention_name>
    <description>1 dose of IPV Vaccine</description>
    <arm_group_label>IPV Vaccine (infants)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy

          2. Subjects/Parents have been informed properly regarding the study and signed the
             informed consent form

          3. Subject/parents/legal guardians will commit themselves to comply with the instructions
             of the investigator and the schedule of the trial.

        Exclusion Criteria For adults-adolescent-children:

          1. Subject concomitantly enrolled or scheduled to be enrolled in another trial

          2. Evolving mild, moderate or severe illness, especially infectious diseases or fever
             (axillary temperature ³ 37.5°C)

          3. Known history of allergy to any component of the vaccines

          4. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular
             injection

          5. Subject who has received in the previous 4 weeks a treatment likely to alter the
             immune response (intravenous immunoglobulins, blood-derived products, corticosteroid
             therapy and other immunosuppresant).

          6. Any abnormality or chronic disease which according to the investigator might interfere
             with the assessment of the trial objectives

          7. Pregnancy &amp; lactation (Adults)

          8. Individuals who have previously received any vaccines against typhoid fever.

          9. Subjects already immunized with any vaccine within 1 month prior and expect to receive
             other vaccines within 1 month following immunization.

         10. Individuals who have a previously ascertained typhoid fever within 3 months prior to
             immunization.

         11. History of substance abuse (Adults).

         12. Subject planning to move from the study area before the end of study period.

        Exclusion Criteria for infants:

          1. Subject concomitantly enrolled or scheduled to be enrolled in another trial

          2. Mother less than 18 years of age at the age of enrollment of the infant

          3. Evolving mild, moderate or severe illness, especially infectious diseases or fever
             (axillary temperature ³ 37.5°C)

          4. Known history of allergy to any component of the vaccines

          5. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular
             injection

          6. Subject who has received in the previous 4 weeks a treatment likely to alter the
             immune response (intravenous immunoglobulins, blood-derived products, corticosteroid
             therapy and other immunosuppresant).

          7. Any abnormality or chronic disease which according to the investigator might be
             compromised by the vaccination and/or interfere with the assessment of the trial
             objectives.

          8. Individuals who have previously received any vaccines against typhoid fever.

          9. Subjects already immunized with any vaccine within 1 month prior and expect to receive
             other vaccines within 1 month following immunization, except MR vaccine.

         10. Individuals who have a previously ascertained typhoid fever within 3 months prior to
             immunization.

         11. Subject planning to move from the study area before the end of study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernie Endyarni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, University of Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novilia Sjafri Bachtiar, MD</last_name>
    <phone>62222033755</phone>
    <phone_ext>14101</phone_ext>
    <email>novilia@biofarma.co.id</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mita Puspita, MD</last_name>
    <phone>62222033755</phone>
    <phone_ext>14100</phone_ext>
    <email>mita.puspita@biofarma.co.id</email>
  </overall_contact_backup>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2018</study_first_submitted>
  <study_first_submitted_qc>March 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

